未知生产厂商
SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
SSR126517E is a biotinylated form of idraparinux. It can be neutralized with intravenous recombinant avidin. Avidin binds biotinylated fondaparinux with high affinity, and the complex is then rapidly cleared. SSR126517E also has an advantage over idraparinux in that an antidote is available when rapid reversal is required. None of the new agents has a specific antidote except SSR126517E. The lack of an antidote in other anticoagulants agents has been a major cause for the development of SSR126517E.
Investigated for use/treatment in thrombosis and venous thromboembolism.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
